GLP1R and diabetes mellitus: Suppression of glucagon action on target organs may be a secondary mechanism underlying the antihyperglycemic efficacy of GLP-1 analogs and DPP-4 inhibitors [31], but there are no approved treatments for diabetes that directly target glucagon secretion or glucagon action in target organs.